TY - JOUR
T1 - Serial serum MCA measurements in the follow-up of breast cancer patients
AU - Merimsky, Ofer
AU - Inbar, Moshe
AU - Hareuveni, Mara
AU - Witenberg, Bruria
AU - Wolman, Yoram
AU - Chaitchik, Samario
PY - 1991/11
Y1 - 1991/11
N2 - Mucin-like carcinoma-associated antigen (MCA) was serially assayed in 58 women with histologically proven breast cancer after their treatment for primary disease. MCA sensitivity and specificity were 87.5% and 76.9%, respectively, and the positive predictive value 82.4%. 10 patients had elevated MCA and no evidence of disease (NED) during their follow-up, of whom 4 finally developed overt metastases. The 4 had a mean (S.D.) MCA value of 46.48 (18.26) U/ml during the lead time, versus 18.76 (2.69) U/ml in the other 6, who are still at high risk for developing overt metastases. Raised levels of MCA in patients with NED create a dilemma of "treat" versus "wait and see". Early treatment of patients with serially uprising MCA levels should be evaluated in a prospective randomised study to assess its ability to prevent or delay the development of overt metastatic disease and influence survival.
AB - Mucin-like carcinoma-associated antigen (MCA) was serially assayed in 58 women with histologically proven breast cancer after their treatment for primary disease. MCA sensitivity and specificity were 87.5% and 76.9%, respectively, and the positive predictive value 82.4%. 10 patients had elevated MCA and no evidence of disease (NED) during their follow-up, of whom 4 finally developed overt metastases. The 4 had a mean (S.D.) MCA value of 46.48 (18.26) U/ml during the lead time, versus 18.76 (2.69) U/ml in the other 6, who are still at high risk for developing overt metastases. Raised levels of MCA in patients with NED create a dilemma of "treat" versus "wait and see". Early treatment of patients with serially uprising MCA levels should be evaluated in a prospective randomised study to assess its ability to prevent or delay the development of overt metastatic disease and influence survival.
UR - http://www.scopus.com/inward/record.url?scp=0025955589&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(91)90027-B
DO - 10.1016/0277-5379(91)90027-B
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0025955589
VL - 27
SP - 1440
EP - 1444
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
SN - 0277-5379
IS - 11
ER -
